| Content | Strength of recommendation | Level of evidence |
| Patients with diabetes are recommended to take blood lipid test at the time of diagnosis and every year thereafter. | I | E |
| In addition to the routine lipid testing (total cholesterol, HDL-C, LDL-C, triglyceride), non-HDL-C or apoB may be measured to assess diabetic dyslipidemia. | IIa | A |
| In diabetic patients without CVD, the recommended target for LDL-C is <100 mg/dL. | I | A |
| In diabetic patients with CVD risk factors or target organ damage such as albuminuria and chronic kidney disease, an LDL-C target of <70 mg/dL should be considered. | I | B |
| Patients with diabetes and dyslipidemia must engage in aggressive lifestyle modifications. | I | A |
| Strict glycemic control is helpful to control hypertriglyceridemia. | I | C |
| Statin is the first line treatment for patients with diabetes and dyslipidemia. | I | A |
| If statin therapy is not sufficient to achieve the target LDL-C goal in patients with diabetes and CVD, adding ezetimibe should be considered. | IIa | B |
| If statin therapy is not sufficient to achieve the target LDL-C goal in patients with diabetes and CVD, adding PCSK9 inhibitors may be considered. | IIb | B |